Figure 5 | Scientific Reports

Figure 5

From: The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients

Figure 5

Expression levels of glutamatergic receptors in the brain of parkinsonian monkeys. Protein expression levels of the (a–c, h–j) NMDARs subunits (a,h) GluN1, (b,i) GluN2A, (c,j) GluN2B, (d–e, k–l) AMPAR subunits (d,k) GluA1 and (e,l) GluA2/3, and (f,g, m,n) metabotropic glutamate receptors (f,m) mGluR2/3 and (g,n) mGluR5 were detected in the (a–g) putamen and (h–n) substantia nigra of untreated (control), MPTP- and (MPTP + L-DOPA)-treated monkeys (n = 5 monkeys/treatment)by Western blotting. (m) N.D. indicates that protein levels were not detectable. Proteins variations are expressed as percentage of the control group. Representative blots of each subunit or receptor immunodensity comparing the experimental groups are shown above the graph. Tubulin was used to normalize for variations in loading and transfer. Dots represent the single subjects’ values while bars illustrate the means ± SEM.

Back to article page